HEALTH OUTCOMES RESEARCH
Burden of disease studies
- CHRYSTAL observational study: Socioeconomic costs of type 1 diabetes mellitus in pediatric patients in Spain
- Costs related to psoriatic arthritis
- Estimation of the economic and social burden of COPD in Extremadura
- Chapter on disease burden in the Ankylosing Spondylitis Atlas compared to a new approach
Social return on investment studies
- Impacto clínico, asistencial, económico y social del manejo actual de la psoriasis en comparación con un nuevo abordaje. SROI Psoriasis
- Impacto clínico, asistencial, económico y social del manejo actual de la insuficiencia cardiaca en comparación con un nuevo abordaje. SROI Insuficiencia Cardiaca
- Análisis y validación de la metodología SROI desde la óptica de la Economía de la salud.
- Impacto clínico, asistencial, económico y social del manejo actual de la Esclerosis Múltiple en comparación con un nuevo abordaje.
Economic evaluation studies
- Estudio piloto de costes y resultados en salud de pacientes con Mieloma Múltiple en un Servicio de Hematología
- Análisis Coste-Beneficio de tratamientos para pacientes asmáticos
- Estudio de Coste Efectividad de la aplicación del CPAP en pacientes con síndrome de apneas-hipopneas durante el sueño
- Coste-efectividad de una unidad monográfica de asma.
- Servicio de riesgo cardiovascular en farmacias comunitarias de la provincia de Toledo: Recogida de datos y análisis estadístico
- Explotación de los resultados de la Encuesta Nacional de Salud 2012 de las personas con incontinencia urinaria en España
- Explotación de los resultados de la encuesta nacional de salud 2012 de las personas con EPOC en España
- Explotación de los resultados de la encuesta nacional de salud 2012 de las personas con Diabetes en España
- La obesidad como factor de riesgo de enfermedades crónicas a partir de los datos de la ENS 2012
- Calidad de vida, salud autopercibida y consumo de recursos de las personas obesas tipo II y superiores (IMC>35) a partir de la ENS 2012
- Explotación de los resultados de la encuesta nacional de salud 2012 de las personas con depresión crónica en España
HEALTH AFFAIRS & POLICY RESEARCH
Health and pharmaceutical policy reports
- The evaluation, financing, and regulation of innovative drugs in developed countries
- Regulation, financing, and promotion policies for biosimilar drugs in the OECD
- The value of medication from a social perspective. Policies for incentivizing generic drugs in the EU
- Criteria for financing and reimbursement of orphan drugs
- The introduction of biosimilars in Spain: estimation of savings for the National Health System (SNS)
Multi-criteria decision analysis studies
- A Multi-Criteria Decision Analysis applied to the field of chronic inflammatory diseases
- Multi-Criteria Decision Analysis in the healthcare field: utility and limitations in decision-making
- A Multi-Criteria Decision Analysis applied to hereditary angioedema
- Analysis of criteria for vaccine procurement in Spain: in search of an ideal sustainable model.
Methodological best practice guides
- Methodological Guide for Economic Evaluation applied to orphan drugs
- Methodological guide for estimating costs associated with diabetes.
- Estimation of the administration cost of a biological drug for the treatment of Non-Hodgkin Lymphoma in the NHS
- Cost estimation study of intravenous administration of biologicals in Day Hospitals in Spain. The impact of obesity on healthcare resource consumption in Spain
- Systematic literature review of economic evaluations of treatments for diabetes mellitus
- Cost studies of type 2 diabetes: a literature review
- Systematic literature review on the efficacy and safety of metformin in patients with Type 2 Diabetes Mellitus
- Applicability of multi-indication pricing
- A critical analysis of value-based oncology frameworks using the example of metastatic prostate cancer
HEALTH ECONOMICS & MARKET ACCESS
Pharmacoeconomics Tools: Economic Evaluations (AMC - ACE - ACU - ACB)
- Adaptation to the Spanish National Health System of the cost-utility analysis of a treatment for patients diagnosed with prostate cancer
- Adaptation to CatSalut of the cost-utility analysis of a treatment for patients diagnosed with prostate cancer
- Cost-Minimization Analysis of a treatment for Acute Lymphoblastic Leukemia
- Adaptation for Spain of the cost-utility analysis of a drug for Gaucher’s disease
- Adaptation to the Spanish National Health System of the cost-effectiveness analysis of a drug for the treatment of acute postoperative pain
- Adaptation to the Spanish National Health System of the cost-effectiveness analysis of a drug for the treatment of gastrointestinal stromal tumors
- Adaptation of the cost-utility analysis of a drug for the treatment of limbal stem cell deficiency
- Adaptation of a cost-utility analysis of a drug for the treatment of schizophrenia
- Cost-effectiveness analysis of the use of a medical device in stress urinary incontinence
- Cost-effectiveness analysis of a drug for the treatment of hyperphosphatemia in chronic kidney disease in Spain
- Development of the cost-utility analysis of oral anticoagulants in atrial fibrillation
- Cost-utility analysis of transdermal patches in the treatment of post-herpetic neuralgia
- Cost-effectiveness analysis of a drug for the treatment of stable chronic angina Economic evaluation of second-generation low molecular weight heparin for primary prevention of venous thromboembolism after total hip or knee arthroplasty
- Adaptation to the Spanish National Health System of a cost-minimization analysis of a drug for the treatment of chronic nephropathy
- Cost-utility analysis of an anti-TNF biological drug in the treatment of rheumatoid arthritis
- Adaptation to the Spanish National Health System of a cost-effectiveness analysis of an anti-TNF biological drug for the treatment of psoriatic arthritis
- Adaptation to the Spanish National Health System of a cost-effectiveness analysis of an anti-TNF biological drug for the treatment of axial spondyloarthritis
- Adaptation of the budget impact analysis of a chemotherapeutic drug for the treatment of advanced breast cancer in Spain.
- Adaptation of the budget impact analysis to the autonomous communities of the budget impact of a chemotherapeutic drug for the treatment of advanced breast cancer
- Budget Impact (BIM) Analysis and assessment of relevant variables in Spain for the development of an economic model in pulmonary arterial hypertension
- Adaptation to the Spanish National Health System of the budget impact analysis of a treatment for patients diagnosed with prostate cancer
- Adaptation to CatSalut of the budget impact analysis of a treatment for patients diagnosed with prostate cancer Programming of the budget impact of a treatment for patients diagnosed with prostate cancer in iPad format
- Budget Impact Analysis of a treatment for Acute Lymphoblastic Leukemia Adaptation to the Spanish National Health System of the budget impact analysis of a treatment for hemophilia B Development of a budget impact for a drug for the treatment of hemophilia A and B in Spain
- Adaptation to the Spanish National Health System of the budget impact analysis of a drug for the treatment of gastrointestinal stromal tumors
- Budget impact of the use of glucose meters with higher accuracy
- Adaptation for Spain of the long-term budget impact analysis of increased longevity of an implantable automatic defibrillator
- Development of the budget impact analysis of a drug for the prophylaxis of renal transplant rejection
- Development of a budget impact model for the introduction of a drug in the prophylactic treatment of graft rejection in renal transplantation in Spain
- Adaptation to the Spanish National Health System of the budget impact analysis of a drug for the treatment of an ultra-rare disease
Price and financing dossiers
- Development of the pricing and reimbursement dossier for a treatment for Acute Lymphoblastic Leukemia
- Development of the pricing and reimbursement dossier for the treatment of hemophilia B in Spain
- Development of the pricing and reimbursement dossier for the treatment of hemophilia A and B in Spain
- Adaptation to Spain of the international value dossier developed for a drug for the treatment of Gaucher’s disease
- Adaptation to the Spanish National Health System of the value dossier for a drug for the treatment of acute postoperative pain
- Development of a clinical and economic value dossier for a thickening agent for the management of patients with dysphagia in Spain
- Development of a Value dossier for a drug for patients with asthma and COPD
- Adaptation to the Spanish National Health System of the value dossier for a drug for the treatment of gastrointestinal stromal tumors
- Adaptation to the Spanish National Health System of the value dossier for a drug for the treatment of cystic fibrosis
- Adaptation to the Spanish National Health System of the value dossier for a drug for the treatment of COPD
- Value dossier for a drug for the treatment of hyperphosphatemia in chronic kidney disease in Spain
- Adaptation to the Spanish National Health System of the value dossier for a drug for the treatment of limbal stem cell deficiency
- Adaptation to the Spanish National Health System of the value dossier for a drug for the treatment of an ultra-rare disease
- Development of a value dossier for a drug for the treatment of schizophrenia
- Value dossier for a drug for the treatment of sickle cell anemia in Spain
- Adaptation to the Spanish National Health System of the value dossier for an anti-TNF biological drug for the treatment of psoriatic arthritis
- Adaptation to the Spanish National Health System of the value dossier for an anti-TNF biological drug for the treatment of axial spondyloarthritis
- Value dossier for a chemotherapeutic drug for the treatment of advanced breast cancer in Spain
- Adaptation to the autonomous communities of the value dossier for a chemotherapeutic drug for the treatment of advanced breast cancer
- Development of a Therapeutic Positioning Report for a drug for schizophrenia
- Development of a Therapeutic Positioning Report for a drug for acquired hemophilia
- Development of a Therapeutic Positioning Report for a drug for Acute Lymphoblastic Leukemia
- Development of a Therapeutic Positioning Report for a drug for Gaucher’s disease
- Development of a Therapeutic Positioning Report for a drug for the treatment of COPD
- Development of a Therapeutic Positioning Report for a drug for the treatment of limbal stem cell deficiency
- Development of a Therapeutic Positioning Report for a drug for the treatment of schizophrenia
- Development of a Therapeutic Positioning Report for a chemotherapeutic drug for advanced breast cancer
- Database of direct and indirect costs of diabetes in five European countries: Germany, Spain, France, Italy, and the United Kingdom
- Database of direct costs associated with chronic pain in Spain
- Database of direct costs of psoriatic arthritis in 6 countries: Germany, Spain, United States, France, Italy, and the United Kingdom
- Database of direct costs of multiple sclerosis in the United States
- Database of direct costs of castration-resistant metastatic prostate cancer in France
- Database of direct healthcare costs of non-valvular atrial fibrillation in Mexico and Russia
- Database of direct costs of multiple myeloma in four European countries: Germany, Spain, France, and Italy
- Database of direct costs of hemophilia in five European countries: Germany, Spain, France, Italy, and the United Kingdom
- Database of direct and indirect costs of osteoporosis in Denmark
- Database of direct and indirect costs of rheumatoid arthritis in: Denmark, Germany, Spain, France, Hungary, Italy, Poland, Romania, Sweden, and the United Kingdom Stakeholders
- Database in Oncology-Hematology Stakeholders Database in Biosimilars in Dermatology
- Study of costs in cutaneous psoriasis and other dermatological conditions
- Development of a budget impact analysis of mesenchymal stem cell treatment in five chronic diseases throughout the patient’s lifetime
- Costs of type II diabetes mellitus: GECOD model
- Programming of type II diabetes mellitus costs on iPad: GECOD model
- Estimation of the improvement in quality of life and years of life gained in atypical hemolytic uremic syndrome following the introduction of a drug in Spain
- The introduction of biosimilars in Spain. Estimation of savings for the National Health System
- Long-term fiscal impact of Assisted Reproductive Therapies in Spain
- Economic burden of type II diabetes mellitus: GECOD model
- Programming of economic burden of type II diabetes mellitus on iPad: GECOD model
- The economic burden of epithelial ovarian cancer in Spain: OVARCOST study
- Monograph of an anti-TNF biological drug. Clinical and pharmacoeconomic attributes in dermatology
- Monograph of a drug for cystic fibrosis
MEDICAL EDUCATION, PRESS & PUBLISHING
Continuous training of the SNS
- How to conduct an Economic Evaluation study and publish it?
- Economic evaluation of medications: practical applications for a regional pharmacy service
- Economic evaluation: practical applications in the hospital setting
- Economic evaluation: from theory to practice. Tools for conducting Economic Evaluation and budget impact studies
- Review of Economic Evaluation studies: practical workshop on critical reading
- Economic evaluation of medications: practical applications for a Health Department
- Leadership and management course for Hematology department heads. Orphan drugs in the current healthcare environment
- Economic evaluation of medications: practical applications for Primary Care Pharmacists
- Leadership and management course: Building confidence to achieve results
- In-person course for primary care pharmacists. GRADE method
- Pharmacoeconomics for hematologists
- Economic evaluation for professionals in the Public Administration of the National Health System
- In-person and online course for primary care pharmacists
- Critical analysis of advances in Economic Evaluation
- Network meta-analysis and R program
- In-person training course on SPSS
- Online course for neurologists
Economic Evaluation Workshops: Generics and by Medical Specialty
- Pharmacoeconomics Workshops for Pulmonologists and Allergists
- Pharmacoeconomics Workshops for Hematologists
- Pharmacoeconomics Workshops for Hospital
- Pharmacists Pharmacoeconomics Workshops in Rheumatology
- Pharmacoeconomics Workshops in Ophthalmology
- Training Workshop on Economic Evaluation of Drugs for Rare Diseases
- Pharmacoeconomics Workshops applied to Urologists
- Pharmacoeconomics Workshops applied to Oncology and Hematology Medications
- Pharmacoeconomics Workshops for HIV Specialists
- Pharmacoeconomics Workshops. New Challenges in Prostate Cancer: From Clinical Practice to Pharmacoeconomics
- Pharmacoeconomics Workshops applied to Clinicians and Pharmacists of SESCAM (Healthcare Service of Castilla-La Mancha)
- The Role of Pharmacoeconomics in Decision-making for Food Supplementation
- Pharmacoeconomics Workshop for Pharmaceutical Care Units (FAP)
- Workshop on Agreements and Financing
- Pharmacoeconomics Workshop for Public Health Technicians
- Workshop on Social Media and Professional Opportunities for FIR (Pharmaceutical Internship Resident)
- Economic Evaluation of Drugs and Optimal Market Access Strategies
- Pharmacoeconomics and Market Access Training for Specialized Sales Force in the Respiratory Area
- Pharmacoeconomics and Market Access Training for the Sales Network of a Specific Product Line
- Economic Evaluation of Devices and Optimal Market Access Strategies
- The Role of Pharmacoeconomics in Decision Making
- Economic Evaluation of Drugs and Optimal Market Access Strategies
- Pharmacoeconomics and its Role in the Therapeutic Positioning of Oncology Drugs in Clinical Practice Guidelines
- Pharmacoeconomics Applied to Decision Making
- Pharmacoeconomics Workshop for Hospital Pharmacists, Oncologists, and Hematologists. Murcia
- Pharmacoeconomics and its Role in the Therapeutic Positioning of Onco-Hematological
- Drugs in Andalusia
- Economic Evaluation for Oncologists in the National Health System
- Healthcare Professionals and the Future of Healthcare in Spain
- Aragon: Pharmacological Innovations in Oncology and Economic Efficiency: What Should We Consider?
- Castilla y León: Pharmacological Innovations in Oncology and Economic Efficiency: What Should We Consider?
- Decision Making Based on Health Outcomes
- Innovation, Quality of Care, Humanization, and Sustainability
- Humanization and Healthcare Delivery
- Workshop on Innovative Contracting Agreements in the Healthcare Sector
- Workshop on HTA Cooperation in Europe: Towards a Stable Model
PUBLICATIONS
- Health Assessment Notebooks
- Applied Pharmacoeconomics Book in Hematology
- White Paper on the Socioeconomic Burden of COPD
- Methodological Guide for Estimating Costs Associated with Diabetes
- Methodological Guide for Economic Evaluation Applied to Orphan Drugs
- White Paper on the Socioeconomic Burden of Urinary Incontinence in Spain
- White Paper on the Socioeconomic Burden of Prostate Cancer in Spain
- Multi-Criteria Decision Analysis in the Healthcare Field: Utility and Limitations in Decision Making
- Scientific Journal on Rare Diseases
